NCT07209241View on ClinicalTrials.gov

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2042

Study Completion Date

November 1, 2042

Conditions
Recurrent Glioblastoma
Interventions
BIOLOGICAL

CART-EGFR-IL13Ra2 T cells

CART-EGFR-IL13Ra2 cells are autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER